Semaglutide Week 38: What to Expect at This Stage

Expected Weight Loss at Week 38

Clinical data and patient experience suggest that by week 38, cumulative weight loss on semaglutide 2.4 mg typically falls in the range of 15 to 16 percent of starting body weight. The rate of weekly weight loss at this stage is generally between 0.3 and 0.8 pounds per week, which is notably slower than the 1 to 2 pounds per week that many patients experienced during the first few months of treatment.

This slower pace is physiologically normal and expected. As body weight decreases, the body's energy expenditure also decreases, narrowing the caloric deficit that drives weight loss. Additionally, metabolic adaptation means the body becomes more efficient at using fewer calories. These are not signs of treatment failure but rather normal biological responses to sustained weight loss.

For a detailed understanding of how semaglutide dosing affects weight loss patterns, including why the maximum dose of 2.4 mg is typically maintained through this stage of treatment, consult our comprehensive dosage guide.

Body Composition Changes at Week 38

Body composition changes at week 38 are often more significant than weight changes alone suggest. Patients frequently report that while the scale may move more slowly, their body shape continues to change. Visceral fat, the metabolically dangerous fat surrounding internal organs, continues to decrease even as overall weight loss slows. This shift has profound implications for long-term health outcomes, even if it is less visible on a daily weigh-in.

Research published alongside the STEP trials indicates that approximately 40 percent of weight lost on semaglutide is fat-free mass, with the remaining 60 percent being fat mass. Patients who engage in regular resistance training may improve this ratio, losing a higher proportion of fat while preserving more lean tissue. This is why exercise guidance is an essential complement to semaglutide therapy.

Side Effects at Week 38

By week 38, most patients have fully adapted to semaglutide, and side effects are typically minimal. The gastrointestinal effects that characterized early treatment are usually well behind patients at this stage. Occasional mild effects may still occur, particularly around dietary indiscretions, but these serve more as feedback signals about eating patterns than as troublesome symptoms requiring management.

If you are experiencing persistent or new side effects at week 38, it is important to discuss these with your healthcare provider. While rare at this stage, new symptoms may indicate the need for clinical evaluation or dose adjustment. For a comprehensive overview of potential effects at any treatment stage, see our guide to semaglutide side effects.

Psychological Adjustment and Mindset

Psychologically, week 38 can present both opportunities and challenges. On the positive side, patients have established new habits, experienced meaningful physical changes, and often report improved self-confidence and quality of life. The challenge is that the slower pace of weight loss can sometimes lead to frustration or the temptation to discontinue treatment prematurely. This is where having a supportive medical team becomes particularly valuable.

Many patients find it helpful to focus on non-scale victories at this stage: improved energy levels, better sleep quality, reduced joint pain, enhanced mobility, improved lab values, and greater confidence in social situations. These outcomes are often more meaningful indicators of treatment success than the number on the scale, particularly at week 38 when weight loss may be approaching its natural plateau.

Long-Term Health Benefits

The long-term health benefits at week 38 extend well beyond weight loss. Patients often see continued improvements in inflammatory markers, insulin sensitivity, and cardiovascular risk factors. Studies suggest that the cardiovascular benefits of semaglutide may be partly independent of weight loss, meaning that patients who continue treatment may see health improvements even after weight loss has plateaued.

Patients interested in understanding the full spectrum of GLP-1 medication benefits should review our complete GLP-1 guide, which covers the cardiovascular, metabolic, and emerging therapeutic applications of this medication class. Additionally, comparing semaglutide with tirzepatide may be relevant for patients considering alternative or complementary treatment options.

Maintenance Strategies for Week 38 and Beyond

Maintenance planning becomes increasingly important at week 38. Patients should be discussing long-term treatment strategies with their healthcare provider, including whether to continue at the current dose, explore slight dose adjustments, or begin thinking about eventual transition strategies. The habits and routines established during active treatment will form the foundation for long-term weight maintenance.

Learn more about how Trimi's medical team supports patients through every phase of treatment, from initial dose escalation through long-term maintenance. Our transparent pricing ensures that ongoing treatment remains accessible as your needs evolve.

When to Talk to Your Provider

While week 38 is generally a stable point in semaglutide treatment, there are situations that warrant a conversation with your healthcare provider. Contact your medical team if you experience any new or worsening side effects, if your weight loss has completely stalled for more than 4 to 6 weeks, if you are considering stopping or changing your medication, or if you have questions about transitioning your treatment plan.